• Markets
• News
• Learn

Octave Specialty Group (OSG) just posted its FY 2025 numbers with Q4 total revenue of US$66.9 million and a basic EPS loss of US$0.66, while on a trailing twelve month basis revenue came in at US$251.2 million and EPS at a loss of US$2.09. The company has seen quarterly revenue move from US$65.2 million in Q4 FY 2024 to US$66.9 million in Q4 FY 2025, with basic EPS shifting from a loss of US$0.46 to a loss of US$0.66 over the same period. This sets the stage for investors to focus squarely on how underwriting margins and overall profitability trends evolve from here.

With the latest figures on the table, the next step is to compare these results against the prevailing narratives around Octave Specialty Group to see which views are backed by the numbers and which might need a rethink.

See what the community is saying about Octave Specialty Group

Losses Still Heavy With US$98.4 Million TTM Net Loss

• On a trailing twelve month basis to Q4 FY 2025, OSG recorded a net loss from continuing operations of US$98.4 million on US$251.2 million of revenue, with basic EPS at a loss of US$2.09.
• Bears highlight that forecasts point to OSG staying unprofitable over the next three years, and the current US$2.09 trailing EPS loss together with the US$98.4 million net loss aligns with that concern, even though five year data shows losses have been shrinking and revenue has been growing at about 20.3% annually.
  • This supports the bearish focus on ongoing earnings pressure, as the business is still generating sizeable accounting losses despite the larger top line.
  • At the same time, the historical 37.2% annual reduction in losses provides some counterpoint to the bearish view that the business model cannot progress toward smaller losses over time.

Bears argue that the earnings drag could persist even as revenue grows, so it is worth seeing how that claim stacks up against the detailed bear case in 🐻 Octave Specialty Group Bear Case

Combined Ratios Above 100% Signal Underwriting Strain

• Where disclosed, OSG’s combined ratios for FY 2025 were above 100%, at 102.1% in Q1, 106.7% in Q2, and 112.9% in Q3, compared with 100.5% in Q3 FY 2024 and 101.6% on a trailing basis at Q4 FY 2024, pointing to underwriting that is not yet covering claims and expenses.
• Analysts with a more cautious stance point to these triple digit combined ratios as evidence that expansion in specialty P&C and MGAs is still coming with elevated costs, while the bullish narrative expects technology and data analytics to help loss ratios and expenses over time.
  • The move from a 100.5% combined ratio in Q3 FY 2024 to 112.9% in Q3 FY 2025 illustrates why skeptics flag underwriting discipline and expense control as key pressure points.
  • Bullish investors looking for margin improvement will likely focus on whether these ratios move closer to or below 100% as the specialty platforms mature and scale.

Growing Revenue Versus Low P/S And Analyst Targets

• Trailing twelve month revenue stands at US$251.2 million, with revenue growth referenced at about 20.3% per year, while OSG trades on a P/S of around 1.0x, below the US insurance industry average of 1.1x and peer average of 1.4x.
• Consensus narrative points out that analysts’ average price target of US$16.33 implies a very large upside from the current US$5.09 share price, and when you set that alongside faster revenue growth and a lower P/S multiple than peers, it reinforces the bullish argument that the market is pricing in the current lack of profitability heavily, even as forecasts still call for ongoing revenue expansion and an eventual path to better margins.
  • The gap between the US$16.33 target and US$5.09 spot price highlights how differently the market and analysts are currently valuing OSG’s growth and loss profile.
  • The combination of a 1.0x P/S multiple and 20.3% revenue growth rate is central to the bullish view that the stock could rerate if losses keep narrowing over time.

Bulls argue that this mix of faster revenue growth, a discounted P/S multiple and a US$16.33 target price sets up an interesting long term story, and you can see how they frame that case in more detail in 🐂 Octave Specialty Group Bull Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Octave Specialty Group on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If the mix of bullish and bearish views here feels split, it makes sense to move quickly, check the underlying data yourself, and see what stands out to you, especially around the 1 or more rewards our work has flagged for investors, which you can review in 4 key rewards

Explore Alternatives

OSG is still carrying heavy losses with a US$98.4 million trailing net loss and combined ratios above 100%, which keeps underwriting profitability under pressure.

If you are uncomfortable with that level of ongoing loss and underwriting strain, it is worth scanning 78 resilient stocks with low risk scores to spot businesses with more resilient profiles right now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com